Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard

ETI therapy was not associated with reduced rates of NTM isolation from sputum over the first 2 years of treatment. However, at a species level, two distinct patterns of change were seen with a trend towards a reduction in the isolation of <i>M. intracellulare</i>, while the rates of Mabs isolation remained unchanged. The reasons for this remain unclear at present but highlight the need for ongoing vigilance with screening for NTM in the setting of ETI therapy.